Dr. Laurie Ryan was our guest for the June Alzheimer’s Talks presented by UsAgainstAlzheimer's. Dr. Ryan is Chief of the Dementias of Aging Branch in the Division of Neuroscience at the National Institute on Aging, which is part of the National Institutes of Health (NIH). At the National Institute on Aging, she directs Alzheimer’s disease clinical trials research. Dr. Ryan discussed efforts and plans to improve the pace and quality of clinical trials and clinical research, with an emphasis on better strategies for recruiting volunteers into trials. The NIA currently has 59 ongoing clinical trials, many in early-stage clinical drug development, as well as a number of trials looking at non-pharmacological or lifestyle interventions.

Support the show (https://www.usagainstalzheimers.org)

Dr. Laurie Ryan was our guest for the June Alzheimer’s Talks presented by UsAgainstAlzheimer's. Dr. Ryan is Chief of the Dementias of Aging Branch in the Division of Neuroscience at the National Institute on Aging, which is part of the National Institutes of Health (NIH). At the National Institute on Aging, she directs Alzheimer’s disease clinical trials research.

Dr. Ryan discussed efforts and plans to improve the pace and quality of clinical trials and clinical research, with an emphasis on better strategies for recruiting volunteers into trials. The NIA currently has 59 ongoing clinical trials, many in early-stage clinical drug development, as well as a number of trials looking at non-pharmacological or lifestyle interventions.

Dr. Howard Fillit joined George Vradenburg for this month’s Alzheimer’s Talks presented by UsAgainstAlzheimer's. They discussed a new report he co-authored, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease”. The report proposes a change in how we define a clinically meaningful drug and therefore the framework for FDA approvals of a possible Alzheimer’s treatment. Dr. Fillit is the Founding Executive Director and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation and a founding member of our ResearchersAgainstAlzheimer’s network. 

Support the show (https://www.usagainstalzheimers.org)

Dr. Howard Fillit joined George Vradenburg for this month’s Alzheimer’s Talks presented by UsAgainstAlzheimer's. They discussed a new report he co-authored, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease”. The report proposes a change in how we define a clinically meaningful drug and therefore the framework for FDA approvals of a possible Alzheimer’s treatment.

Dr. Fillit is the Founding Executive Director and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation and a founding member of our ResearchersAgainstAlzheimer’s network.

Author and journalist Greg O’Brien spoke about his journey into Alzheimer’s disease with Meryl Comer. Greg was diagnosed with early onset Alzheimer’s in 2009, and has been writing, chronicling, and talking about the process ever since. He shared his thoughts, strategies, and experiences in a candid and personal conversation.

Support the show (https://www.usagainstalzheimers.org)

Author and journalist Greg O’Brien spoke about his journey into Alzheimer’s disease with Meryl Comer. Greg was diagnosed with early onset Alzheimer’s in 2009, and has been writing, chronicling, and talking about the process ever since. He shared his thoughts, strategies, and experiences in a candid and personal conversation.

Debra Lappin was the guest host for our March Alzheimer’s Talks. She spoke with Dr. Gregory Jicha, Professor of Neurology and the holder of the Robert T. and Nyles Y. McCowan Endowed Chair in Alzheimer’s Disease at the Sanders-Brown Center on Aging at the University of Kentucky Alzheimer’s Disease Center. Dr. Jicha talked about the impact of genetics on Alzheimer’s risk, how genetic research is affecting the development of medicines, and why individuals with risk genes are important for clinical trials. 

Support the show (https://www.usagainstalzheimers.org)